Medicometrics

Independent analysis of pharmaceuticals and healthcare data through publicly available information.

  • Medicare Part D Biologics and Biosimilars Analysis (2019-2023)

    Biologics are drugs produced from living organisms or containing specific components derived from living organisms. Biosimilars are products similar to biologics in efficacy, composition, and mechanism of action. Biosimilars are considered derivatives of biologics. They are manufactured after the reference product’s (Biologic) patent license expires.

    In this post, we will examine multiple biologics and analyze spending trends for the biosimilars in Medicare Part D. Our primary focus is overall spending, claims trends, and cost per prescription from 2019 to 2023.

    READ MORE

  • Oncology Drugs Spending Trend in Medicare Part D (2019-2023)

    Oncology drugs account for a major share of total Medicare Part D spending due to their high cost. In this blog post, we will perform an exploratory analysis of this critical drug class and its contribution to the Medicare drug coverage program.

    (more…)

  • Evolution of Anticoagulants in Medicare Part D (2019-2023)

    Anticoagulants constitute a significant portion of Medicare Part D spending. Previously, we looked into the contribution of anti-diabetics to the Medicare drug coverage program. In this post, we will explore the role of anticoagulants in Medicare Part D spending (2019-2023).

    (more…)

  • Trend Analysis of SGLT2 Inhibitors in Medicare Part D (2019-2023)

    In the previous post, GLP-1 agonists’ analysis revealed an extraordinary increase of 327% in spending over the years. This enormous increase makes us wonder about the trends of other anti-diabetics. In this post, we will explore the contribution of another drug class named SGLT2 Inhibitors to Medicare Part D spending.

    (more…)

  • The Rise of GLP-1 Drugs in Medicare Part D (2019-2023)

    The previous analysis revealed that a large portion of Medicare Part D spending was concentrated in a small number of drugs. Among all drug classes, GLP-1 agonists emerged as a clear winner. In this post, we will examine the contribution of GLP-1 drugs to Medicare Part D spending over the years (2019-2023).

    (more…)

  • Top 10 Medicare Part D Drugs Over the Years (2019-2023)

    In the previous post, we discussed how Medicare Part D spending increased by 48% from 2019 to 2023. We noticed that a small number of drugs accounted for a large share of total expenditures. This leads us to wonder which drugs are the primary drivers of the spending growth. Were all of these drugs consistent over the five years?

    In this blog post, we will explore the drugs that made it onto the top ten list over the years and how their growth changed with time.

    (more…)

  • What are the Factors Driving Medicare Part D Spending (2019-2023)?

    Medicare Part D spending increased from approximately $220 billion in 2019 to $326 billion over five years (2019-2023). It’s a significant increase of approximately 48%. In this post, we will explore the possible causes behind the increasing expenditure.

    (more…)

  • Changing Trends in Medicare Part D Spending (2019–2023)

    Medicare Part D aims to provide financial assistance to people, enabling them to buy prescribed drugs at reduced cost. It is available to people who are already part of the Medicare program. This drug coverage program effectively reduces the financial burden on the public.

    The following post is an analysis of publicly available Medicare Part D drug spending data for the years 2019-2023. It may seem outdated, as we are currently in 2026. However, data collection and recordkeeping usually take years to complete. So, the data used for analysis is the latest available record published by the Centers for Medicare and Medicaid Services(CMS) on its official website.

    (more…)